Immune intervention in type 1 diabetes - PubMed (original) (raw)

Review

Immune intervention in type 1 diabetes

Aaron W Michels et al. Semin Immunol. 2011 Jun.

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the specific immune destruction of insulin producing beta cells. Currently there is no cure for T1D and treatment for the disease consists of lifelong administration of insulin. Immunotherapies aimed at preventing beta cell destruction in T1D patients with residual c-peptide or in individuals developing T1D are being evaluated. Networks of researchers such as TrialNet and the Immune Tolerance Network in the U.S. and similar networks in Europe have been established to evaluate such immunotherapies. This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies.

PubMed Disclaimer

Figures

Figure 1

Hypothetical stages and loss of beta cells in an individual progressing to type 1A diabetes. Reproduced with permission from Eisenbarth, GS. From

www.barbardaviscenter.org

Figure 2

Pancreatic section from a type 1 diabetic pancreatic organ donor showing lobular destruction of insulin producing beta cells in islets. On the left, there are islets with beta cells stained for insulin while the islets on the right lack beta cells and insulin staining. The histology section comes from the JDRF nPOD program,

www.jdrfnpod.org

Figure 3

Anti-CD3 monoclonal antibody treatment delays loss of C-peptide in new onset patients with type 1 diabetes. From Herold et al Diabetes 54:1763-9, 2005.

Cited by

Particle-Based therapies for antigen specific treatment of type 1 diabetes.
Rose Lukesh N, Middleton DD, Bachelder EM, Ainslie KM. Rose Lukesh N, et al. Int J Pharm. 2023 Jan 25;631:122500. doi: 10.1016/j.ijpharm.2022.122500. Epub 2022 Dec 15. Int J Pharm. 2023. PMID: 36529362 Free PMC article. Review.
Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.
Lombardi A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, Tomer Y. Lombardi A, et al. J Autoimmun. 2020 Dec;115:102543. doi: 10.1016/j.jaut.2020.102543. Epub 2020 Sep 17. J Autoimmun. 2020. PMID: 32951964 Free PMC article.
Mulberry Leaf Regulates Differentially Expressed Genes in Diabetic Mice Liver Based on RNA-Seq Analysis.
Ge Q, Zhang S, Chen L, Tang M, Liu L, Kang M, Gao L, Ma S, Yang Y, Lv P, Kong M, Yao Q, Feng F, Chen K. Ge Q, et al. Front Physiol. 2018 Aug 7;9:1051. doi: 10.3389/fphys.2018.01051. eCollection 2018. Front Physiol. 2018. PMID: 30131712 Free PMC article.
Tolerogenic Nanoparticles to Treat Islet Autoimmunity.
Neef T, Miller SD. Neef T, et al. Curr Diab Rep. 2017 Aug 8;17(10):84. doi: 10.1007/s11892-017-0914-z. Curr Diab Rep. 2017. PMID: 28791576 Free PMC article. Review.
Treatment of Diabetes Mellitus Using iPS Cells and Spice Polyphenols.
Ge Q, Chen L, Chen K. Ge Q, et al. J Diabetes Res. 2017;2017:5837804. doi: 10.1155/2017/5837804. Epub 2017 Jul 3. J Diabetes Res. 2017. PMID: 28758131 Free PMC article. Review.

References

1. Eisenbarth GS. Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes. Diabetes. 2010;59(4):759–774. - PMC - PubMed
1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293–1300. - PMC - PubMed
1. Maahs DM, Rewers M. Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done. J Clin Endocrinol Metab. 2006;91(10):3757–3759. - PubMed
1. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832–836. - PubMed
1. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet. 2008;371(9626):1777–1782. - PubMed

Immune intervention in type 1 diabetes - PubMed (original) (raw)